TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
$100.40
-$4.08(-5.19%)
At close: 4:00 PM EST
$100.40
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$62.23 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)1.04M
Market Cap
$3.44B
Enterprise Value$3.44B
Total Cash (Recent Filing)$488.37M
Total Debt (Recent Filing)$469.69M
Price to Earnings (P/E)21.7
Beta1.25
Next Earnings
May 05, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.62
Shares Outstanding34,302,452
10 Day Avg. Volume1,259,737
30 Day Avg. Volume1,042,523
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.67
Enterprise Value/Gross Profit9.47
Enterprise Value/Ebitda23.14
Forecast
1Y Price Target
$160.30Price Target Upside59.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)2.5
Revenue Forecast (FY)$739.12M
Bulls Say, Bears Say
Bulls Say
European ExpansionInternational launch of the organ procurement network across multiple European countries could materially expand the addressable market and lift device and service revenue as adoption increases.
Kidney Program OpportunityAdvancement of the kidney program could become the company's largest organ initiative, substantially increasing transplant volumes and aligning payer incentives for improved outcomes, supporting long-term revenue upside.
Liver Transplant DemandGrowth in liver transplant surgeries supports increased demand for TransMedics' organ preservation systems, which could drive higher device utilization and revenue.
Bears Say
Data And Forecast RiskReliance on partial registry data for transplant volume estimates creates risk that projections may be revised downward if volumes slow, undermining revenue and model assumptions.
Heart Transplant DeclineDeclining heart transplant surgeries reduce demand for a key TransMedics application, creating downside pressure on device sales tied to that segment.
Organ Management Proposal RiskA public proposal to form an organ management organization could provoke negative reactions from existing organ procurement groups and temporarily reduce donor volumes, introducing revenue volatility.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $62.23 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $3.44B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is May 05, 2026 which is in 32 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Feb 27, 2026. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $0.436 by $2.184.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.62.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,302,452 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $2.62 in its last earnings report, beating expectations of $0.436. Following the earnings report the stock price went up 1.198%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$160.30 (59.66% Upside)
$160.30 (59.66% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.06%
12-Months-Change
Fundamentals
Return on Equity
53.88%
Trailing 12-Months
Asset Growth
35.04%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust revenue growth (Q4 +32% YoY; FY +37%), expanded operating margins, a healthy cash balance (~$488M), large increases in OCS clinical volume (5,139 U.S. OCS transplants in 2025) and clear growth catalysts across clinical programs, next-generation platforms and international rollout. Notable near-term risks include Q4 gross margin pressure, a significant one-time tax benefit inflating net income, low lung adoption, potential trial delays due to competitive dynamics in ENHANCE Part B, and planned 2026 investments that will compress margins temporarily. On balance, the positives — scalable revenue growth, margin expansion at scale, strong cash position and accelerating clinical adoption in liver and heart — outweigh the lowlights, though execution on trials, international buildout and operational scaling remains critical.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$160.30
▲(59.66% Upside)
Technical Analysis
Ownership Overview
3.51% Insiders
42.45% Mutual Funds
24.35% Other Institutional Investors
5.62% Public Companies and Individual Investors